tbuckley/cabot-search huggingface dataset:
Establishment of an International Registry of Patients with Inherited FXIII Deficiency.
Authors: Vytautas Ivaskevicius, Rainer Seitz, Hans P. Kohler, Laszlo Muszbek, Robert A.S. Ariens, Erhard Seifried, Akitada Ichinose, Diane J. Nugent, Johannes Oldenburg
Journal: Blood (2007)
Heat Shock Treatment Enhances Graft Cell Survival in Skeletal Myoblast Transplantation to the Heart
Authors: Ken Suzuki, Ryszard T. Smolenski, Jay Jayakumar, Bari Murtuza, Nigel J. Brand, Magdi H. Yacoub
Journal: Circulation (2000)

Background —Graft survival after skeletal myoblast transplantation is affected by various pathological processes caused by environmental stress. Heat shock is known to afford protection of several aspects of cell metabolism and function. We hypothesized that prior heat shock treatment of graft cells would improve their survival after cell transplantation. Methods and Results —L6 rat skeletal myoblasts expressing β-galactosidase (β-gal) were subjected to heat shock (42°C, 1 hour). Increased expression of heat shock protein 72 was detected 24 hours later in the heat-shocked cells. After hypoxia-reoxygenation in vitro, lactate dehydrogenase leakage was significantly attenuated in the heat-shocked cells; in addition, the percentage of early apoptosis was lower in this group measured by flow cytometry with annexin V staining. For the in vivo study, 1×10 6 heat-shocked (hsCTx) or normal-cultured (CTx) myoblasts were infused into the explanted rat hearts through the coronary artery followed by heterotopic heart transplantation. β-gal activity was significantly higher in the hsCTx group after cell transplantation, with an estimated 8×10 6 surviving cells per heart in the hsCTx group and 5×10 6 cells in the CTx group on day 28. Discrete loci of grafted cells were globally observed in the myocardium of the hsCTx and CTx groups, with a higher frequency in the hsCTx group. Surviving myoblasts occasionally differentiated into myotubes and had integrated with the native cardiomyocytes. Conclusions —Heat-shocked skeletal myoblasts demonstrated improved tolerance to hypoxia-reoxygenation insult in vitro and enhanced survival when grafted into the heart. Heat shock treatment could be useful in improving graft cell survival in cell transplantation.
Does quality influence choice of hospital?
Authors: H. S. Luft
Journal: JAMA (1990)

In recent years, much information has been provided to the public and to physicians about hospital quality measured in terms of patient outcomes. To examine if, before these public data releases, quality influenced the attractiveness of a hospital to referring or admitting physicians and to patients, we estimated the influences of quality, charges, ownership, and distance on the choice of hospitals for patients with seven surgical procedures and five medical diagnoses in hospitals in three geographic areas in California in 1983. Greater distance and public or proprietary ownership consistently reduced the likelihood of selection while medical school affiliation increased the likelihood of selection. For five of seven surgical procedures and two of five medical diagnoses, hospitals with poorer than expected outcomes attracted significantly fewer admissions. The reverse held for two surgical procedures and one medical diagnosis. The results suggest that quality played an important role in choices among hospitals even before explicit data were widely available. (<i>JAMA</i>. 1990;263:2899-2906)
The effect of antiviral therapy on t(14;18) translocation and immunoglobulin gene rearrangement in patients with chronic hepatitis C virus infection
Authors: Eli Zuckerman, Tsila Zuckerman, Dvora Sahar, Sara Streichman, Dina Attias, Edmond Sabo, Daniel Yeshurun, Jacob M. Rowe
Journal: Blood (2001)
Correction: Reducing serum cholesterol
Authors: Andrew Welch
Journal: BMJ (1993)

exploitation by the imperial powers than any population explosion.Today, as Third World countries become more marginalised in the world economy and less able to maintain debt repayments it is their desperation, poverty, and stagnation that determine their inclusion in the "developing" world.While the world economy leaves millions with no access to clean water or medical or food supplies and pays Western farmers to leave pro- ductive land fallow, Smith highlights the "evidence ... that many women are crying out for access to contraceptives."Population must be kept "on the agenda from the United Nations to the village council," but until the prevailing assumptions are replaced with critical scientific, social, and political investigation there will be no solutions.
1.5-year post-treatment follow-up of radium-223 dichloride (Ra-223) safety in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases from the phase 3 ALSYMPCA study.
Authors: Chris Parker, Nicholas J. Vogelzang, A. Oliver Sartor, David Bottomley, Robert E. Coleman, Irene Skjorestad, Mona Wahba, Sten Nilsson
Journal: Journal of Clinical Oncology (2014)

5070 Background: Ra-223, an alpha-emitting pharmaceutical, significantly improved overall survival and was well tolerated in ALSYMPCA (Parker, NEJM2013). Long-term safety monitoring of Ra-223 is essential to build a complete safety profile and identify any association with secondary malignancies. Here we report adverse events (AEs) from ALSYMPCA patients (pts) ~1.5 y after last pt’s final injection (inj). Methods: All ALSYMPCA pts were to enter designated follow-up starting 4 wk after each pt’s last inj to 3 y after first inj. Only treatment (tx)-related AEs and specific diseases (acute myelogenous leukemia [AML], myelodysplastic syndrome [MDS], aplastic anemia [AA], primary bone cancer, primary cancer in other organs) were reported. Results: Of 921 pts (Ra-223, n = 614; pbo, n = 307), 574 entered designated ALSYMPCA follow-up (Ra-223, n = 406; pbo, n = 168). 335/406 (83%) Ra-223 pts and 119/168 (71%) pbo pts had 6 inj. Median follow-up time was 10.4 mo for Ra-223 pts and 7.6 mo for pbo pts. In the safety population, 25/404 (6%) Ra-223 pts and 8/167 (5%) pbo pts had 37 tx-related AEs (Table). Overall, myelosuppression incidence was ≤3%. No pts had AML, MDS, or primary bone cancer; 1 Ra-223 pt had AA, and 2 Ra-223 pts and 3 pbo pts had primary cancer in other organs (Table). Conclusions: Long-term follow-up of ~1.5 y after last pt’s final inj showed no new safety concerns or secondary malignancies related to Ra-223. Clinical trial information: NCT00699751. ALSYMPCA Follow-up, n (%) Ra-223 n = 404* Pbo n = 167* All Gr Gr 3/4 All Gr Gr 3/4 Hematologic AEs Anemia 11 (3) 5 (1) 5 (3) 1 (1) Aplastic anemia 1 (< 1) 1 (< 1) 0 0 Leukopenia 2 (< 1) 2 (< 1) 0 0 Neutropenia 2 (1) 2 (1) 0 0 Thrombocytopenia 4 (1) 0 0 0 Nonhematologic AEs Cardiopulmonary failure 0 0 1 (1)† 0 Nausea 0 0 1 (1) 0 Fatigue 0 0 1 (1) 0 General physical health deterioration 1 (< 1) 0 0 0 Multiorgan failure 1 (< 1)† 0 0 0 Pneumonia 1 (< 1)† 0 0 0 Weight decrease 1 (< 1) 0 0 0 Anorexia 1 (< 1) 0 0 0 Musculoskeletal pain 1 (< 1) 0 0 0 Pathologic fracture 2 (< 1) 1 (< 1) 0 0 Dizziness 1 (< 1) 0 0 0 Primary cancers not tx related · Bladder · Squamous cell carcinoma · Lymph node mets not originating from prostate · Adenocarcinoma rectosigmoid · Skin * Safety population. †Gr 5.
Liver biopsy size matters in chronic hepatitis: Bigger is better
Authors: P Scheuer
Journal: Hepatology (2003)

Improved survival of children with CF has increased our need to understand the relevance of cystic fibrosis-associated liver disease (CFLD). We assessed the impact of liver disease and disease severity on the survival of children with cystic fibrosis.A real life, single center cohort study with 27 years follow up was conducted. Mild CFLD was diagnosed as children with abnormal serum liver function tests and abnormal ultrasound. Advanced CFLD was established by detection of cirrhosis or portal hypertension. A directed acyclic graph, Kaplan-Meier (KM) and Cox regression analysis were used to model survival.290 patients were enrolled, 48 (16.5%) had mild CFLD and 55 (19%) had advanced CFLD. Ten children with advanced CFLD and 1 with mild CFLD died. Based on the KM analysis, the mean (SE) overall survival age of all CF children was 29.1 years (0.50). The mean (SE) survival among females with advanced CFLD was 24.7 years (1.58) compared to 30.4 years (0.66) for females without advanced CFLD (p = 0.0027). Advanced CFLD was a predictor of decreased survival when adjusted for sex and diabetes (HR 2.54, 95%CI 1.05–6.15, p = 0.039). Mild CFLD was not associated with decreased survival. The effect of advanced CFLD on survival was mainly borne by females (HR = 6.37, 95%CI 1.62–25.06 vs. males, HR = 1.00, 95%CI 0.25–4.01).Advanced but not mild CFLD was associated with an increased risk of death when adjusted for sex and diabetes, and resulted in premature death in females with cystic fibrosis by approximately 6 years.
"ENDORSED BY PHYSICIANS."
Journal: JAMA (1900)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
index to advertisers
Journal: JAMA (1985)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Urban Particle-Induced Apoptosis and Phenotype Shifts in Human Alveolar Macrophages
Authors: Andrij Holian, Raymond F. Hamilton, Maria T. Morandi, Steven D. Brown, Li Li
Journal: Environmental Health Perspectives (1998)

Epidemiological studies report a small but positive association between short-term increases in airborne particulate matter and small increases in morbidity and mortality from respiratory and cardiovascular disease in urban areas. However, the lack of a mechanistic explanation to link particle exposure and human health effects makes it difficult to validate the human health effects. The present study tested the hypothesis that urban particles could cause apoptosis of human alveolar macrophages(AM) and a shift of their phenotypes to a higher immune active state, which would provide a mechanism to explain an inflammatory response. Freshly isolated human AM were incubated for 24 hr with urban particles (#1648 and #1649), Mount Saint Helen's ash (MSH), and residual oil fly ash (ROFA).Cell viability was assessed by trypan blue exclusion and apoptosis was demonstrated by morphology, cell death ELISA, and DNA ladder formation. Additionally, AM were characterized according to RFD1(+) (immune stimulatory macrophages) and RFD1(+)7(+) (suppressor macrophages) phenotypes by flow cytometry. ROFA particles caused AM necrosis at concentrations as low as 10 microg/ml, urban particles had no effect except at 200 microg/ml, and MSH had no effect at 200 microg/ml. ROFA (25 microg/ml) and particles #1648 or #1649 (100 microg/ml) caused apoptosis of AM by all three criteria, but 200 microg/ml MSH had no effect. Finally, 25 microg/ml ROFA and 100 microg/ml particles #1648 or #1649 up regulated the expression of the RFD1(+) AM phenotype, while only ROFA decreased the RFD1(+)7(+) phenotype. Consequently, ROFA and urban particles can induce apoptosis of human AM and increase the ratio of AM phenotypes toward a higher immune active state (i.e., increased RFD1(+):RFD1(+)7(+) ratio). Ifurban particles cause similar changes in vivo, this could result in lung inflammation and possible increased pulmonary and cardiovascular disease.
VISPA: a Computational pipeline for the identification and analysis of genomic vector integration sites
Authors: Andrea Calabria, Simone Leo, Fabrizio Benedicenti, Daniela Cesana, Giulio Spinozzi, Massimilano Orsini, Stefania Merella, Elia Stupka, Gianluigi Zanetti, Eugenio Montini
Journal: Genome Medicine (2014)

The analysis of the genomic distribution of viral vector genomic integration sites is a key step in hematopoietic stem cell-based gene therapy applications, allowing to assess both the safety and the efficacy of the treatment and to study the basic aspects of hematopoiesis and stem cell biology. Identifying vector integration sites requires ad-hoc bioinformatics tools with stringent requirements in terms of computational efficiency, flexibility, and usability. We developed VISPA (Vector Integration Site Parallel Analysis), a pipeline for automated integration site identification and annotation based on a distributed environment with a simple Galaxy web interface. VISPA was successfully used for the bioinformatics analysis of the follow-up of two lentiviral vector-based hematopoietic stem-cell gene therapy clinical trials. Our pipeline provides a reliable and efficient tool to assess the safety and efficacy of integrating vectors in clinical settings.
Timolol: new antiglaucoma agent works by a different mechanism
Authors: M. Annexton
Journal: JAMA (1979)

For the first time in 25 years, a new drug was approved last fall for the treatment of glaucoma. "It works almost like magic," says Thom Zimmerman, MD, of the Department of Ophthalmology, Louisiana State University, New Orleans. Timolol maleate was released as a topical ocular hypotensive agent in September by the Food and Drug Administration. Extensive studies and clinical tests, Zimmerman told a recent meeting of the International Glaucoma Congress (III) in Las Vegas, have proved that the drug is extremely effective against open angle glaucoma, the most common form of the disease. In addition, there are few side effects so far, thus eliminating the compliance problems so common with the use of other glaucoma medications. "It doesn't change pupil size, vision, or accommodation," Zimmerman says. "What it does is decrease the formation of aqueous humor. This is just the opposite of other glaucoma medications that enhance the outflow
ERRORS IN OBSERVATION.
Journal: JAMA (1905)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
VIENNA
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
UNDESCENDED TESTES
Authors: Heinrich Lamm
Journal: JAMA (1960)

<h3>To the Editor:—</h3> The author of the answer to the question on undescended testes inThe Journal, June 11, page 742 states, "... since only 12% of testicular tumors occur in undescended testes, surgical exploration can be delayed until such time as more definite indications exist." This I cannot understand. I do not know the incidence of undescended testes, but I would guess it is but a fraction of 1%. If tumor development in testes had nothing to do with testicular ectopy, then the incidence of ectopy should be the same in testes, tumorous and non-tumorous, i. e., the incidence of ectopy in testes with tumors should also be only a fraction of 1%. It is much higher in tumor-bearing testes, suggesting a causal connection between ectopy and malignant changes. Thus, the statistical information in the expert's answer is a strong argument for removal of undescended testes, not against it. To
Health-Related Quality-of-Life Measures— United States, 1993
Journal: JAMA (1995)

Measures of health-related quality of life (HR-QOL) are used to evaluate the outcomes of interventions and the need for health services (1,2). HR-QOL includes how persons perceive their own health--which reliably predicts loss of function, morbidity, and mortality (3-5)--and how well they function physically, psychologically, and socially during usual daily activities. Measures of HR-QOL are important because they assess dysfunction and disability not reflected by standard measures of morbidity and mortality. Since January 1993, the Behavioral Risk Factor Surveillance System (BRFSS) has included four HR-QOL questions regarding overall self-rated health and recent physical health, mental health, and activity limitation (6). This report describes 1993 BRFSS results for state-specific differences in these measures of HR-QOL.
Informed opinion on informed consent
Authors: N. J. Demy
Journal: JAMA (1971)

<h3>To the Editor.—</h3> As a radiologist who has been sued, I have reflected earnestly on advice to obtain Informed Consent but have decided to "take the risks without informing the patient" and trust to "God, judge, and jury" rather than evade responsibility through a legal gimmick. I even thought of devising an Informed Consent for my type of practice along the lines of Burnham's (<i>Science</i><b>152</b>:448-449,1966) after a New York verdict affirmed a patient's right to be informed. Burnham's form for surgical patients differs a bit from Dr. Alfidi's (<b>216</b>:1325-1329, 1971), but has juicy possibilities. President Truman had a sign on his desk to remind him that "the buck stops here." So with the physician. He may not be God, judge, and jury, but he is their surrogate and must speak alone with the patient as Moses did with God on Mt. Sinai. Think what the Ten Commandments
THE CHANGE.
Journal: JAMA (1883)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
International Abstracts
Journal: JAMA (1993)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal